These discrepant results could underlie the fact that gemcitabine and 5-FU do not induce immunogenic tumor cell death; consequently, these drugs do not favor the cross presentation of tumor antigens by DCs and CD8+ T cell activation [56]. Here, CD8A is linked to neoplasm.